Phagenesis Limited

Phagenesis develops Phagenyx®, a targeted pharyngeal electrical stimulation therapy designed to restore swallowing control in patients with post-stroke dysphagia and other neurogenic swallowing disorders. The company combines neuroscience research, clinical evidence, and medical-device innovation to improve recovery and reduce the burden of dysphagia care.